Granted Patent B2

US 12,459,921 · App. 17/281,419 · Granted Nov 4, 2025

Inventors: Xiaohua Chen (Shanghai, CN); Jia Li (Shanghai, CN); Yu Cheng (Shanghai, CN); Yubo Zhou (Shanghai, CN); Huijun Nie (Shanghai, CN); Yujie Wang (Shanghai, CN); Hongtao Tian (Shanghai, CN); Weijuan Kan (Shanghai, CN); Tian Mi (Shanghai, CN); Xiaobei Hu (Shanghai, CN); Binshan Zhou (Shanghai, CN); Kenian Yan (Shanghai, CN); Gaoya Xu (Shanghai, CN); Yuhua Zhong (Shanghai, CN); Lei Feng (Shanghai, CN)

Assignee: Shanghai Institute of Materia Medica, Chinese Academy of Sciences

C07D401/14A61K45/06C07D401/04C07D405/14C07D409/14C07D413/14C07D417/14C07D471/10C07D491/107C07D495/04C07D498/20

Abstract

Claims (470)

1. A compound represented by formula (I) or a tautomer, enantiomer, diastereomer, racemate, isotopic compound, pharmaceutically acceptable salt, ester, or hydrate thereof:

wherein, X 1 is —CH 2 — or —O—;

X 2 is —CH 2 — or —CO—;

R 1 is hydrogen, deuterium, fluorine or linear or branched C 1 -C 6 hydrocarbon group;

R 2 and R 4 are each independently hydrogen or deuterium;

R 3 is hydrogen, deuterium or halogen;

L is a substituted or unsubstituted linear alkylene group containing 2-8 carbon atoms, and the “substituted” means that one or more hydrogen atoms in the alkylene group are optionally substituted by the following substituents: deuterium, halogen, carbonyl, hydroxyl, amino, cyano, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, —NHC(O) Ra 1 , —NHC(O)ORa 2 , —NRa 3 Ra 4 , wherein Ra 1 , Ra 2 , Ra 3 and Ra 4 are each independently selected from hydrogen, C 1-6 alkyl unsubstituted or substituted by halogen, hydroxyl, cyano, or nitro, and C 3-6 cycloalkyl unsubstituted or substituted by halogen, hydroxyl, cyano, or nitro;

Y is absent, —CO— or —CO—NH—, the corresponding placement of Y, A and L is A-L-, A-CO-L-, and A-CO—NH-L-, A is: i) heterocyclyl selected from the following:

X 3 is N;

n 4 is 0, 1, 2 or 3;

n 5 is 0, 1, 2 or 3,

Y 1 is hydrogen, deuterium, halogen, cyano, carboxyl, nitro, hydroxyl, amino, aminocarbonyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxyl, C 1 -C 6 haloalkyl, or C 1 -C 6 haloalkoxyl;

Y 2 is substituted or unsubstituted 6-10 membered aryl, or substituted or unsubstituted 6-10 membered heteroaryl, wherein the substituted 6-10 membered aryl or 6-10 membered heteroaryl is substituted by one or more substituents selected from: deuterium, halogen, cyano, nitro, hydroxyl, aminocarbonyl, C 1 -C 3 alkyl, C 1 -C 3 alkoxyl, C 1 -C 3 alkylcarbonyl, C 1 -C 3 alkoxycarbonyl, C 1 -C 3 alkylsulfonyl, C 1 -C 3 alkylaminocarbonyl, C 3 -C 6 cycloalkyl or heterocyclyl, C 1 -C 3 acylamino, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxyl;

Y 3 is substituted or unsubstituted 6-10 membered aryl, or substituted or unsubstituted 6-10 membered heteroaryl, wherein the substituted 6-10 membered aryl or 6-10 membered heteroaryl is substituted by one or more substituents selected from: deuterium, halogen, cyano, nitro, hydroxyl, aminocarbonyl, C 1 -C 3 alkyl, C 1 -C 3 alkoxyl, C 1 -C 3 alkylcarbonyl, C 1 -C 3 alkoxycarbonyl, C 1 -C 3 alkylsulfonyl, C 1 -C 3 alkylaminocarbonyl, C 3 -C 6 cycloalkyl or heterocyclyl, C 1 -C 3 acylamino, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxyl;

Y 4 and Y 5 are absent, or one or more substituents on the heterocyclic ring, Y 4 and Y 5 are each independently deuterium, halogen, oxo, C 1 -C 3 alkyl, C 3 cycloalkyl, C 1 -C 3 haloalkyl or phenyl;

ii) fused heterocyclyl selected from:

X 4 is C, N or O;

n 6 is 0, 1, 2 or 3;

n 7 is 0, 1, 2 or 3;

n 8 is 0, 1, 2, 3 or 4;

 is 6-10 membered aryl ring or 5-10 membered heteroaryl ring;

R 8 is each independently selected from hydrogen, deuterium, C 1 -C 3 alkoxyl, halogen, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl, carboxyl, C 1 -Czalkylaminocarbonyl, C 1 -C 3 alkoxycarbonyl, nitro, amino, cyano, C 1 -C 3 haloalkyl, hydroxyl, C 1 -C 3 alkylsulfonyl, C 1 -C 3 alkylamino, C 1 -C 3 acylamino, aminocarbonyl, C 3 -C 6 heterocyclyl, C 1 -C 3 haloalkoxyl, phenyl or 5-6 membered heteroaryl;

with the proviso that when Ra is selected from the following substituents: hydrogen, deuterium, C 1 -C 3 alkoxyl, halogen, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl, carboxyl, C 1 -C 3 alkyl aminocarbonyl, C 1 -C 3 alkoxycarbonyl, nitro, amino, cyano, C 1 -C 3 haloalkyl, hydroxyl, C 1 -C 3 alkylsulfonyl, and Y is absent, then X 1 is other than —O—;

Y 6 and Y 7 are absent, or one or more substituents on the heterocyclic ring independently selected from deuterium, halogen, C 1 -C 3 alkyl, C 3 cycloalkyl, C 1 -C 3 haloalkyl;

or iii) spiroheterocyclic group selected from:

n c1 is 0, 1, 2 or 3;

n c2 is 0, 1, 2 or 3;

n c3 is 1, 2 or 3;

n 9 is 0, 1, 2, 3 or 4;

 is 6-10 membered aryl ring or 5-10 heteroaryl ring;

R 9 is independently selected from the following substituents: deuterium, halogen, cyano, nitro, hydroxyl, amino, C 1 -C 3 alkylamino, C 1 -C 3 acylamino, aminocarbonyl, linear or branched C 1 -C 6 alkyl, linear or branched C 1 -C 6 alkoxyl, C 3 -C 6 cycloalkyloxyl, C 3 -C 6 cycloalkyl or heterocycloalkyl, C 1 -C 3 alkylaminocarbonyl, C 1 -C 3 alkoxycarbonyl, C 1 -C 3 alkylsulfonyl, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxyl, phenyl, 5-6 membered heteroaryl;

R 10 and R 11 are independently selected from hydrogen, substituted or unsubstituted 6-10 membered aryl, substituted or unsubstituted 5-10 membered heteroaryl, and the species of substituent is the same as the above-mentioned substituent R 9 on the

 ring;

Y 8 is a substituent which optionally replaces the hydrogen atom in the non-aromatic moiety of the spiro ring structure, and Y 8 is optionally substituted by deuterium, halogen, C 1 -C 3 alkyl, C 3 cycloalkyl or C 1 -C 3 haloalkyl.

2. The compound of claim 1 , or the tautomer, enantiomer, diastereomer, racemate, isotopic compound, pharmaceutically acceptable salt, ester, or hydrate thereof,

wherein X 1 is —CH 2 — or —O—;

X 2 is —CH 2 — or —CO—;

R 1 is hydrogen, deuterium, fluorine or C 1 -C 3 linear or branched hydrocarbon group;

R 2 and R 4 are each independently hydrogen or deuterium;

R 3 is hydrogen, deuterium or halogen;

L is a substituted or unsubstituted linear alkylene group comprising 2-8 carbon atoms, and the “substituted” means that one or more hydrogen atoms in the alkylene group are optionally replaced by substituents selected from: deuterium, halogen, carbonyl, hydroxyl, amino, cyano, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 3 -C 6 cycloalkyl, —NHC(O) Ra 1 , —NHC(O)ORa 2 , —NRa 3 Ra 4 , wherein Ra 1 , Ra 2 , Ra 3 and Ra 4 are each independently selected from hydrogen, C 1-6 alkyl substituted by halogen, hydroxyl, cyano, or nitro, and C 3-6 cycloalkyl substituted by halogen, hydroxyl, cyano, or nitro

Y is absent or —CO— or —CO—NH—, the corresponding placement of Y, A and L is A-L-, A-CO-L- or A-CO—NH-L-, A is:

i) heterocyclyl selected from the following:

wherein, Y 1 is hydrogen, deuterium, halogen, cyano, carboxyl, nitro, hydroxyl, amino, aminocarbonyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxyl, C 1 -C 6 haloalkyl, or C 1 -C 6 haloalkoxyl;

Y 2 is substituted or unsubstituted 6-10 membered aryl or substituted or unsubstituted 6-10 membered heteroaryl, wherein the substituted 6-10 membered aryl or 6-10 membered heteroaryl is substituted by one or more of the following substituents: deuterium, halogen, cyano, nitro, hydroxyl, aminocarbonyl, C 1 -C 3 alkyl, C 1 -C 3 alkoxyl, C 1 -C 3 alkylcarbonyl, C 1 -C 3 alkoxycarbonyl, C 1 -C 3 alkylsulfonyl, C 1 -C 3 alkylaminocarbonyl, C 3 -C 6 cycloalkyl or heterocyclyl, C 1 -C 3 acylamino, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxyl;

Y 3 is substituted or unsubstituted 6-10 membered aryl, or substituted or unsubstituted 6-10 membered heteroaryl wherein the substituted 6-10 membered aryl or 6-10 membered heteroaryl is substituted by one or more of the following substituents: deuterium, halogen, cyano, nitro, hydroxyl, aminocarbonyl, C 1 -C 3 alkyl, C 1 -C 3 alkoxyl, C 1 -C 3 alkylcarbonyl, C 1 -C 3 alkoxycarbonyl, C 1 -C 3 alkylsulfonyl, C 1 -C 3 alkylaminocarbonyl, C 3 -C 6 cycloalkyl or heterocyclyl, C 1 -C 3 acylamino, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxyl;

Y 4 and Y 5 are absent, or one or more substituents on the heterocyclic ring, Y 4 and Y 5 are each independently deuterium, halogen, oxo, C 1 -C 3 alkyl, C 3 cycloalkyl or phenyl;

ii) fused heterocyclyl selected from:

n 8 is 0, 1, 2, 3 or 4;

X 4 is C, N or O;

 is 6-10 membered aryl ring or 5-10 membered heteroaryl ring,

R 8 is each independently selected from hydrogen, deuterium, C 1 -C 3 alkoxyl, halogen, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl, carboxyl, C 1 -C 3 alkylaminocarbonyl, C 1 -C 3 alkoxycarbonyl, nitro, amino, cyano, C 1 -C 3 haloalkyl, hydroxyl, C 1 -C 3 alkylsulfonyl, C 1 -C 3 alkylamino, C 1 -C 3 acylamino, aminocarbonyl, C 3 -C 6 heterocyclyl, C 1 -C 3 haloalkoxyl, phenyl or 5-6 membered heteroaryl;

with the proviso that when the above R 8 is each independently selected from any of the following substituents: hydrogen, deuterium, C 1 -C 3 alkoxyl, halogen, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl, carboxyl, C 1 -C 3 alkylaminocarbonyl, C 1 -C 3 alkoxycarbonyl, nitro, amino, cyano, C 1 -C 3 haloalkyl, hydroxyl, C 1 -C 3 alkylsulfonyl, and when Y is absent, then X 1 is other than —O—;

Y 6 and Y 7 are absent, or one or more substituents on the heterocyclic ring, and each is independently selected from deuterium, halogen, C 1 -C 3 alkyl, C 3 cycloalkyl, C 1 -C 3 haloalkyl;

or iii) spiroheterocyclic group selected from:

wherein, n 9 is 0, 1, 2, 3 or 4:

 is 6-10 membered aryl ring or 5-10 heteroaryl ring;

R 9 is independently selected from the following substituents: deuterium, halogen, cyano, nitro, hydroxyl, amino, C 1 -C 3 alkylamino, C 1 -C 3 acylamino, aminocarbonyl, linear or branched C 1 -C 6 alkyl, linear or branched C 1 -C 6 alkoxyl, C 3 -C 6 cycloalkyloxyl, C 3 -C 6 cycloalkyl or heterocycloalkyl, C 1 -C 3 alkylaminocarbonyl, C 1 -C 3 alkoxycarbonyl, C 1 -C 3 alkylsulfonyl, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxyl, phenyl, 5-6 membered heteroaryl; wherein when n 9 >1, each R 9 can be the same or different;

Y 8 is a substituent which optionally replace the hydrogen atom in the non-aromatic moiety of the spiro ring structure, and Y 8 is optionally substituted by deuterium, halogen, C 1 -C 3 alkyl, C 3 cycloalkyl or C 1 -C 3 haloalkyl.

3. The compound of claim 1 , or the tautomer, enantiomer, diastereomer, racemate, isotopic compound, pharmaceutically acceptable salt, ester, or hydrate thereof, wherein the compound of formula (I) is the compound of any of formula (I-1) to (I-8):

wherein, X 1 is —CH 2 — or —O—;

X 2 is —CH 2 — or —CO—;

R 1 is hydrogen, deuterium or fluorine;

R 2 and R 4 are each independently selected from hydrogen or deuterium;

R 3 is hydrogen, deuterium or fluorine;

L is substituted or unsubstituted linear alkylene group containing 2-8 carbon atoms, and the “substituted” means that one or more hydrogen atoms in the alkylene group are optionally substituted by the following substituents: deuterium, halogen, cyano, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, —NHC(O) Ra 1 , —NHC(O)ORa 2 , —NRa 3 Ra 4 , wherein Ra 1 , Ra 2 , Ra 3 and Ra 4 are each independently selected from hydrogen, C 1-6 alkyl substituted or unsubstituted by one or more halogens, or C 3-6 cycloalkyl substituted or unsubstituted by one or more halogens;

Y is absent, or is —CO— or —CO—NH—;

n 9 is 0, 1, 2, 3 or 4;

 is a 6-10 membered aryl ring or 5-10 heteroaryl ring,

 is fused with the spiro ring nucleus to form a spiro heterocyclic group;

Y 8 is a substituent which optionally replaces the hydrogen atom in the non-aromatic moiety of the spiro ring structure, and Y 8 is optionally substituted by deuterium, halogen, methyl, ethyl, cyclopropyl, or trifluoromethyl;

R 9 is independently selected from the following substituents: deuterium, halogen, cyano, nitro, hydroxyl, amino, C 1 -C 3 alkylamino, C 1 -C 3 acylamino, aminocarbonyl, linear or branched C 1 -C 6 alkyl, linear or branched C 1 -C 6 alkoxyl, C 3 -C 6 cycloalkyloxyl, C 3 -C 6 cycloalkyl or heterocycloalkyl, C 1 -C 3 alkylaminocarbonyl, C 1 -C 3 alkoxycarbonyl, C 1 -C 3 alkylsulfonyl, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxyl, phenyl, 5-6 membered heteroaryl; wherein when n 9>1 , each R 9 can be the same or different.

4. The compound of claim 1 , or the tautomer, enantiomer, diastereomer, racemate, isotopic compound, pharmaceutically acceptable salt, ester or hydrate thereof, wherein the compound of formula (I) is the compound of any of formula (I-9) to (I-16):

wherein, X 1 is —CH 2 — or —O—;

X 2 is —CH 2 — or —CO—;

R 1 is hydrogen, deuterium or fluorine;

R 2 and R 4 are each independently hydrogen or deuterium;

R 3 is hydrogen, deuterium or fluorine;

L is substituted or unsubstituted linear alkylene group containing 2-8 carbon atoms, and the “substituted” means that one or more hydrogen atoms in the alkylene group are optionally substituted by the following substituents: deuterium, halogen, cyano, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, —NHC(O) Ra 1 , —NHC(O)ORa 2 , —NRa 3 Ra 4 , wherein Ra 1 , Ra 2 , Ra 3 and Ra 4 are each independently selected from hydrogen atom, C 1-6 alkyl substituted or unsubstituted by one or more halogens, or C 3-6 cycloalkyl substituted or unsubstituted by one or more halogens;

Y is absent, or is —CO— or —CO—NH—;

n 9 is 0, 1, 2, 3 or 4;

R 9 is independently selected from the following substituents: deuterium, halogen, cyano, nitro, hydroxyl, amino, C 1 -C 3 alkylamino, C 1 -C 3 acylamino, aminocarbonyl, linear or branched C 1 -C 6 alkyl, linear or branched C 1 -C 6 alkoxyl, C 3 -C 6 cycloalkyloxyl, C 3 -C 6 cycloalkyl or heterocycloalkyl, C 1 -C 3 alkylaminocarbonyl, C 1 -C 3 alkoxycarbonyl, C 1 -C 3 alkylsulfonyl, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxyl, phenyl, 5-6 membered heteroaryl; wherein when n 9 >1, each R 9 can be the same or different;

Y 8 is a substituent which optionally replaces the hydrogen atom in the non-aromatic moiety of the spiro ring structure, and Y 8 is optionally substituted by deuterium, halogen, methyl, ethyl, cyclopropyl, or trifluoromethyl.

5. The compound of claim 1 , or the tautomer, enantiomer, diastereomer, racemate, isotopic compound, pharmaceutically acceptable salt, ester or hydrate thereof, wherein the compound of formula (I) is the compound of any of formula (I-24) to (I-32):

wherein, X 2 is —CH 2 — or —CO—;

R 1 is hydrogen, deuterium or fluorine;

R 2 and R 4 are each independently hydrogen or deuterium;

R 3 is selected from hydrogen, deuterium or fluorine;

L is substituted or unsubstituted linear alkylene group containing 2-8 carbon atoms, and the “substituted” means that one or more hydrogen atoms in the alkylene group are optionally substituted by the following substituents: deuterium, halogen, cyano, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, —NHC(O) Ra 1 , —NHC(O)ORa 2 , —NRa 3 Ra 4 , wherein Ra 1 , Ra 2 , Ra 3 and Ra 4 are each independently selected from hydrogen atom, C 1-6 alkyl unsubstituted or substituted by one or more halogens or C 3-6 cycloalkyl unsubstituted or substituted by one or more halogens;

Y is absent, or —CO— or —CO—NH—;

n 8 , n 9 and n 10 are each independently selected from 0, 1, 2, 3, or 4;

X 4 is C, N or O;

R 9 is selected from the following substituents: deuterium, halogen, cyano, nitro, hydroxyl, amino, C 1 -C 3 alkylamino, C 1 -C 3 acylamino, aminocarbonyl, linear or branched C 1 -C 6 alkyl, linear or branched C 1 -C 6 alkoxyl, C 3 -C 6 cycloalkyloxyl, C 3 -C 6 cycloalkyl or heterocycloalkyl, C 1 -C 3 alkylaminocarbonyl, C 1 -C 3 alkoxycarbonyl, C 1 -C 3 alkylsulfonyl, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxyl, phenyl, 5-6 membered heteroaryl; wherein when n 9 >1, each R 9 can be the same or different;

 is selected from substituted or unsubstituted 6-10 membered aryl, substituted or unsubstituted 6-10 membered heteroaryl, and the 6-10 membered aryl or 6-10 membered heteroaryl is selected from thienyl, pyridyl, phenyl, benzothienyl, benzimidazolyl, indolyl, naphthyl, quinolinyl, isoquinolinyl;

R 10 is each independently selected from deuterium, halogen, cyano, nitro, hydroxyl, aminocarbonyl, C 1 -C 3 alkyl, C 1 -C 3 alkoxyl, C 1 -C 3 alkylcarbonyl, C 1 -C 3 alkoxycarbonyl, C 1 -C 3 alkylsulfonyl, C 1 -C 3 alkylaminocarbonyl, C 3 -C 6 cycloalkyl or heterocyclyl, C 1 -C 3 acylamino, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxyl, when n 10>1 , each R 10 can be the same or different;

R 8 is each independently selected from hydrogen, deuterium, C 1 -C 3 alkoxyl, halogen, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl, carboxyl, C 1 -C 3 alkylaminocarbonyl, C 1 -C 3 alkoxycarbonyl, nitro, amino, cyano, C 1 -C 3 haloalkyl, hydroxyl, C 1 -C 3 alkylsulfonyl, C 1 -C 3 alkylamino, C 1 -C 3 acylamino, aminocarbonyl, C 3 -C 6 heterocyclyl, C 1 -C 3 haloalkoxyl, phenyl or 5-6 membered heteroaryl; wherein when n 8 >1, each R 8 can be the same or different.

6. The compound of claim 1 , or the tautomer, enantiomer, diastereomer, racemate, isotopic compound, pharmaceutically acceptable salt, ester or hydrate thereof, wherein the compound of formula (I) is the compound of any one of formula (I-33) to (I-40):

wherein, X 2 is —CH 2 — or —CO—;

R 1 is hydrogen, deuterium or fluorine;

R 2 and R 4 are each independently hydrogen or deuterium;

R 3 is hydrogen, deuterium or fluorine;

L is substituted or unsubstituted linear alkylene group containing 2-8 carbon atoms, and the “substituted” means that one or more hydrogen atoms in the alkylene group are optionally substituted by the following substituents: deuterium, halogen, cyano, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, —NHC(O) Ra 1 , —NHC(O)ORa 2 , —NRa 3 Ra 4 , wherein Ra 1 , Ra 2 , Ra 3 and Ra 4 are each independently selected from hydrogen atom, C 1-6 alkyl unsubstituted or substituted by one or more halogens or C 3-6 cycloalkyl unsubstituted or substituted by one or more halogens;

Y is absent, or —CO— or —CO—NH—;

n 8 , n 9 and n 10 are each independently 0, 1, 2, 3, or 4;

X 4 is selected from C, N or O;

R 9 are each independently selected from the following substituents: deuterium, halogen, cyano, nitro, hydroxyl, amino, C 1 -C 3 alkylamino, C 1 -C 3 acylamino, aminocarbonyl, linear or branched C 1 -C 6 alkyl, linear or branched C 1 -C 6 alkoxyl, C 3 -C 6 cycloalkyloxyl, C 3 -C 6 cycloalkyl or heterocycloalkyl, C 1 -C 3 alkylaminocarbonyl, C 1 -C 3 alkoxycarbonyl, C 1 -C 3 alkylsulfonyl, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxyl, phenyl, 5-6 membered heteroaryl; when n 9 >1, each R 9 can be the same or different;

is selected from substituted or unsubstituted 6-10 membered aryl, substituted or unsubstituted 6-10 membered heteroaryl, and the 6-10 membered aryl or 6-10 membered heteroaryl is selected from thienyl, pyridyl, phenyl, benzothienyl, benzimidazolyl, indolyl, naphthyl, quinolinyl, isoquinolinyl;

R 10 is each independently selected from deuterium, halogen, cyano, nitro, hydroxyl, #aminocarbonyl, C 1 -C 3 alkyl, C 1 -C 3 alkoxyl, C 1 -C 3 alkylcarbonyl, C 1 -C 3 alkoxycarbonyl, C 1 -C 3 alkylsulfonyl, C 1 -C 3 alkylaminocarbonyl, C 3 -C 6 cycloalkyl or heterocyclyl, C 1 -C 3 acylamino, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxyl, when n 10 >1, each R 10 can be the same or different;

R 8 is each independently selected from hydrogen, deuterium, C 1 -C 3 alkoxyl, halogen, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl, carboxyl, C 1 -C 3 alkylaminocarbonyl, C 1 -C 3 alkoxycarbonyl, nitro, amino, cyano, C 1 -C 3 haloalkyl, hydroxyl, C 1 -C 3 alkylsulfonyl, C 1 -C 3 alkylamino, C 1 -C 3 acylamino, aminocarbonyl, C 3 -C 6 heterocyclyl, C 1 -C 3 haloalkoxyl, phenyl or 5-6 membered heteroaryl; wherein when n 8 >1, each R 8 can be the same or different;

with the proviso that when R 8 is selected from any of the following substituents: deuterium, C 1 -C 3 alkoxyl, halogen, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl, carboxyl, C 1 -C 3 alkylaminocarbonyl, C 1 -C 3 alkoxycarbonyl, nitro, amino, cyano, C 1 -C 3 haloalkyl, hydroxyl, C 1 -C 3 alkylsulfonyl, and when Y is absent, X 1 is other than —O—.

7. A compound selected from the following compounds:

Serial

number

Compound

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

or a tautomer, enantiomer, diastereomer, racemate, isotopic compound, pharmaceutically acceptable salt, ester or hydrate thereof.

8. A method for preparing the compound represented by the general formula (I) of claim 1 , wherein the method is selected from one of the following:

Synthesis method 1:

wherein, the definitions of R 1 , R 2 , R 3 , R 4 and X 2 are the same as those in claim 1 ;

m 1 is an integer from 1 to 7;

has the same definition as i) heterocyclyl, ii) fused heterocyclyl, and iii) spiroheterocyclic group in the definition of A in claim 1 ;

Step 1-1: compound 1C is obtained by Sonogashira coupling reaction of compounds 1A and 1B at room temperature or under heating conditions in the presence of dipole organic solvent, Pd catalyst, monovalent copper catalyst and base;

Step 1-2: compound 1C is reduced to compound 1D by hydrogen under catalytic condition of Pd/C, raney nickel or Wilkinson's catalyst, Step 1-3: compound 1F is obtained by reacting compound 1D with hydroxyquinoline 1E under the condition of triphenylphosphine and diisopropylazodiformate;

Step 1-4: compound 1D is reacted to obtain compound 1G in the presence of triphenylphosphine and carbon tetrabromide;

Step 1-5: compound 1I is obtained by reacting compound 1G with nitrogen-containing heterocyclic compound 1H in the presence of sodium iodide, wherein the compound 1H is amine compound containing A group in claim 1 ;

Synthesis method 2:

wherein, the definitions of R 1 , R 2 , R 3 , R 4 and X 2 are the same as those in claim 1 ;

m 1 is an integer from 1 to 7;

has the same definition as i) heterocyclyl, ii) fused heterocyclyl, and iii) spiroheterocyclic group in the definition of A in claim 1 ;

G2 is a protecting group selected from TBS, Trit or benzyl;

Step 2-1: multi-substituted olefin derivative 2C is obtained by reacting compounds 2A and 2B under heating conditions in the presence of aprotic solvent, Pd catalyst phosphine ligand and organic base;

Step 2-2: compound 2C is reduced to compound 2D by hydrogen under catalytic condition of Pd/C or Wilkinson's catalyst;

Step 2-3: piperidone derivative 2E is obtained by ring-closing reaction in the presence of potassium tert-butoxide in dry tetrahydrofuran;

Step 2-4: compound 2F is obtained by removing the protective group of compound 2E under acidic condition or in the presence of TBAF;

Step 2-5: compound 2F is reacted to obtain compound 2G in the presence of triphenylphosphine and carbon tetrabromide;

Step 2-6: compound 21 is obtained by reacting compound 2G with nitrogen-containing heterocyclic compound 2H in the presence of sodium iodide, wherein the compound 2H is amine compound containing A group in claim 1 ;

Synthesis method 3:

wherein, the definitions of R 1 , R 2 , R 3 , R 4 , and X 2 are the same as those in claim 1 ;

m 2 is an integer from 1 to 7:

has the same definition as i) heterocyclyl, ii) fused heterocyclyl, and iii) spiroheterocyclic group in the definition of A in claim 1 ;

G 3 -NH 2 is various aromatic amine or aliphatic amine compounds used in the examples of the present invention;

Step 3-1: compound 3A and 3B are reacted in the presence of trifluoroacetic anhydride and tert-butanol to obtain compound 3C;

Step 3-2: compounds 3C and 3D are reacted in the presence of potassium carbonate to obtain compound 3E;

Step 3-3: piperidone derivative 3F is obtained by ring-closing of compound 3E in the presence of potassium tert-butoxide;

Step 3-4: compound 3G is obtained by removing the protective group of compound 3F under hydrochloric acid condition;

Step 3-5: compound 3I is obtained by condensation reaction of compound 3G and nitrogen-containing heterocyclic compound 3H in the presence of condensing agent and base, wherein compound 3H is the variety amine compounds containing A group in claim 1 ;

Step 3-6: compound 3G and compound 3J are condensed in the presence of condensing agent and base to obtain compound 3K;

Synthesis method 5:

wherein, the definitions of R 1 , R 2 , R 3 , R 4 , and X 2 are the same as those in claim 1 ;

m 3 is an integer from 1 to 7;

has the same definition as heterocyclyl, fused heterocyclyl, spiroheterocyclic group in the definition of A in claim 1 ;

Ar is 6-10 membered aryl, or 5-10 membered heteroaryl, the aryl or heteroaryl is optionally substituted by one or more R 5 substituents, and R 5 is the same as in claim 1 ;

Step 5-1: compound 5A and 5B are reacted under condition of triphenylphosphine and diisopropyl azodicarboxylate to obtain compound 5C;

Step 5-2: compound 5C is reacted in the presence of potassium carbonate to obtain compound 5D;

Step 5-3: compound 5E is obtained by removing the protective group under hydrochloric acid condition;

Step 5-4: compound 5E and compound 5F are reacted under basic condition to obtain compound 5G;

Step 5-5: compound 5I is obtained by reacting compound 5E with nitrogen-containing heterocyclic Compound 5H under N,N-carbonyldiimidazole and basic condition, wherein the Compound 5H is the amine compound containing A group in claim 1 ;

Synthesis method 6:

wherein, the definitions of R 1 , R 2 , R 3 , R 4 , and X 2 are the same as those in claim 1 ;

m 4 is an integer from 1 to 7;

has the same definition as heterocyclyl, fused heterocyclyl, spiroheterocyclic group in the definition of A in claim 1 ;

Step 6-1: compound 6A and 6B are reacted in the presence of potassium carbonate to obtain compound 6C;

Step 6-2: compound 6C is reacted in the presence of potassium tert-butoxide to obtain compound 6D;

Step 6-3: compound 6F is obtained by reacting compound 6D with nitrogen-containing heterocyclic compound 6E under basic condition, wherein compound 6E is amine compounds containing A group in claim 1 ;

Synthesis method 7

wherein, the definitions of R 1 , R 2 , R 3 , and R 4 are the same as those in claim 1 ;

m 4 is an integer from 1 to 7;

has the same definition as heterocyclyl, fused heterocyclyl, spiroheterocyclic group in the definition of A in claim 1 ;

Step 7-1: compound 7A and 7B chloromethyl methyl ether are reacted in the presence of sodium hydride to obtain compound 7C;

Step 7-2: compound 7C is reacted in the presence of 7D and azodiisobutyronitrile to obtain compound 7E;

Step 7-3: compounds 7E and 7F are reacted under basic condition to obtain compound 7G;

Step 7-4: compound 7G is reacted under acidic condition to obtain compound 7H;

Step 7-5: compound 7I and 7F are reacted under basic condition to obtain compound 7H;

Step 7-6: compound 7H and 6B are reacted in the presence of potassium carbonate to obtain compound 7J;

Steps 7-7: compound 7L is obtained by reacting compound 7J with nitrogen-containing heterocyclic compound 7K under basic condition, wherein the compound 7K is amine compound containing A group in claim 1 .

9. The compound of claim 1 , or the enantiomer, diastereomer, racemate, pharmaceutically acceptable salt, ester or hydrate thereof, for use in regulating the activity of CRL4 CRBN E3 ubiquitin ligase.

10. A pharmaceutical composition, wherein the pharmaceutical composition contains a therapeutically effective dose of the compound of claim 1 , or the enantiomer, diastereomer, racemate, pharmaceutically acceptable salt, ester or hydrate thereof, and at least one pharmaceutically acceptable carrier.

11. A method of treating a disease related to CRL4 CRBN E3 ubiquitin ligase in a subject in need thereof, the method comprising administering to the subject a therapeutically amount of the compound of claim 1 , enantiomer, diastereomer, racemate, pharmaceutically acceptable salt, ester, or hydrate thereof of claim 1 , wherein the diseases is selected from the group consisting of cancer, inflammation, pain, neurological disease and immune system disease.

12. The compounds of claim 2 , or the tautomer, enantiomer, diastereomer, racemate, isotopic compound, pharmaceutically acceptable salt, ester, or hydrate thereof, wherein

ring is selected from the group consisting of benzene ring, pyridine ring, thiophene ring, indole ring, benzothiophene ring, benzimidazole ring, naphthalene ring, quinoline ring and isoquinoline ring.

13. The compounds of claim 3 , or the tautomer, enantiomer, diastereomer, racemate, isotopic compound, pharmaceutically acceptable salt, ester, or hydrate thereof, wherein

is selected from the group consisting of thiophene ring, pyrrole ring, benzene ring, pyridine ring, benzothiophene ring, benzimidazole ring, indole ring, quinoline ring and isoquinoline ring.

14. The compound of claim 1 , or the tautomer, enantiomer, diastereomer, racemate, isotopic compound, pharmaceutically acceptable salt, ester, or hydrate thereof,

wherein

R 1 is hydrogen, deuterium or fluorine;

R 3 is hydrogen, deuterium or fluorine;

L is substituted or unsubstituted linear alkylene group containing 2-8 carbon atoms, and the “substituted” means one or more hydrogen atoms in the alkylene group are optionally replaced by the following substituents: deuterium, halogen, cyano, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, —NHC(O) Ra 1 , —NHC(O)ORa 2 , —NRa 3 Ra 4 , wherein Ra 1 , Ra 2 , Ra 3 and Ra 4 are each independently selected from hydrogen atom, C 1-6 alkyl unsubstituted or substituted by one or more halogens, or C 3-6 cycloalkyl unsubstituted or substituted by one or more halogens;

Y is absent, or is —CO— or —CO—NH—, the corresponding placement of Y, A and L is -A-CO-L-,-A-CO—NH-L-,-A-L-, A moiety comprises at least one nitrogen atom and Y is connected to the nitrogen atom, A is spiroheterocyclic group selected from:

wherein, n 9 is 0, 1, 2, 3 or 4;

R 9 is independently selected from the following substituents: deuterium, halogen, cyano, nitro, hydroxyl, amino, C 1 -C 3 alkylamino, C 1 -C 3 acylamino, aminocarbonyl, linear or branched C 1 -C 6 alkyl, linear or branched C 1 -C 6 alkoxyl, C 3 -C 6 cycloalkyloxyl, C 3 -C 6 cycloalkyl or heterocycloalkyl, C 1 -C 3 alkylaminocarbonyl, C 1 -C 3 alkoxycarbonyl, C 1 -C 3 alkylsulfonyl, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxyl, phenyl, 5-6 membered heteroaryl; wherein when n 9 >1, each R 9 can be the same or different;

Y 8 is a substituent which optionally replace the hydrogen atom in the non-aromatic moiety of the spiro ring structure, and Y 8 is optionally substituted by deuterium, halogen, methyl, ethyl, cyclopropyl, or trifluoromethyl.

Assignments (1)

Priority Claims (1)

Continuity (1)

References Cited (43)